Beam Therapeutics Financial Statements
NASDAQ: BEAMHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Beam Therapeutics revenue and earnings
In fiscal 2025, Beam Therapeutics generated $139.7 million in revenue, up 120.0% from fiscal 2024. Beam Therapeutics reported a net loss of $80.0 million, compared with a loss of $376.7 million a year earlier. Operating margin was -274.6%.
Diluted earnings per share came in at -$0.81. Over the last 5 fiscal years, BEAM's revenue has grown at a 466.3% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Beam Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Revenue | 139.74M | 63.52M | 377.71M | 60.92M | 51.84M | 24.00K | 18.00K |
| Revenue growth (YoY) | +120.01% | -83.18% | +520.01% | +17.51% | +215916.67% | +33.33% | — |
| Operating Expenses | 523.44M | 479.09M | 554.19M | 399.40M | 444.31M | 132.78M | 75.17M |
| Research & Development | 409.62M | 367.56M | 437.38M | 311.59M | 387.09M | 103.18M | 54.62M |
| Operating Income | -383.69M | -415.57M | -176.49M | -338.48M | -392.46M | -132.76M | -75.15M |
| Other Income (Expense) | 303.70M | 38.87M | 45.32M | 78.30M | 21.83M | -61.83M | -3.17M |
| Pretax Income | -79.99M | -376.70M | -131.16M | -260.18M | -370.64M | -194.59M | — |
| Income Tax | 0 | 39.00K | 1.37M | 3.41M | 0 | 0 | 0 |
| Net Income | -79.99M | -376.74M | -132.53M | -289.09M | -370.64M | -194.59M | -78.33M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | -0.81 | -4.58 | -1.72 | -4.13 | -5.77 | -4.19 | -14.05 |
| EPS (Diluted) | -0.81 | -4.58 | -1.72 | -4.13 | -5.77 | -4.19 | -14.05 |
| Shares Outstanding (Basic) | 98.91M | 82.31M | 77.15M | 70.02M | 64.23M | 46.73M | 6.48M |
| Shares Outstanding (Diluted) | 98.91M | 82.31M | 77.15M | 70.02M | 64.23M | 46.73M | 6.48M |
| EBITDA | -361.40M | -393.64M | -156.47M | -324.33M | -385.01M | -128.03M | -71.65M |
| Operating Margin | -274.57% | -654.25% | -46.73% | -555.61% | -757.01% | -553166.67% | -417522.22% |
| Net Margin | -57.24% | -593.13% | -35.09% | -474.54% | -714.91% | -810800.00% | -435144.44% |
This table shows 7 annual periods of Beam Therapeutics's income statement, from FY 2025 back to FY 2019, across 15 line items including revenue, operating expenses, research & development. Values in USD; B = billions, M = millions. Fiscal periods follow BEAM's reporting calendar. What is a income statement?